4Bray F. Transitions in human development and the global cancer bnrden[R]//Wild C P,Stewart B. World cancer report 2014. Ly on : International Agency for Research on Cancer, 2014.
5Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major palterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359- E38G.
6Gabor Miklos G L. The human cancer genome project:one more misstep in the war on cancer[J]. Nat Biotechnol,2005,23(5):535 -537.
7Folkman J. Tumor angiogenesis:therapeutic implications[J]. N En gl J Med, 1971,285(21) : 1182-1186.
8Ellis L M,Reardon D A. Is there really a yin and yang to VEGF targeted therapies?[J]. Lancet Oncol, 2010,11 (9) : 809- 811.
9Dy G K, Adjei A A. Understanding, recognizing, and managing tox icities of targeted anticancer therapies[J]. CA Cancer J Clin,2013 63(4) :249-279.
10Niraula S,Seruga B,Ocana A,et al. The price we pay/or progress:a meta-anaiysis of harms of newly approved antieaneer drogs[J]. J Clin Oncol, 2012,30 (24) : 3012- 3019.
